News zum Sektor Gesundheit aus Schweden

 

Lund, Sweden – January 13, 2026 – The Lund District Court has today accepted Phase Holographic Imaging PHI AB's bankruptcy filing. As part of the process, the court has appointed Niklas Ernulf as bankruptcy trustee. The trustee will oversee the management of the company's assets and liabilities, and ensure an orderly liquidation in accordance with applicable law. PHI will cooperate fully with the trustee to facilitate the process and keep stakeholders informed of significant developments....

HOLZMINDEN (dpa-AFX) - Der Duft- und Geschmacksstoffhersteller Symrise plant den Verkauf seines Terpen-Geschäfts. Dass in diesem Zusammengang sowie auf die schwedische Beteiligung Swedencare (Swedencare ......

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES. Peptonic Medical AB (publ) (”Peptonic” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) in connection with the Company's forthcoming rights issue of units,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KAROLINSKA DEVELOPMENT AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW....

Getinge will issue its Year-End Report 2025 on January 27, 2026, at 08.00 a.m. CET, followed by a conference call at 10.00 a.m. CET, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO. Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link (https://events.inderes.com/getinge/q4-report-2025/dial-in). After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference. During the...

Kontigo Care AB (publ) announces that the company's Chief Financial Officer (CFO), Anja Persson, has decided to conclude her assignment as a consultant and will remain in her role during a transition period. Kontigo Care AB (publ) announces that the company's Chief Financial Officer (CFO), Anja Peters Ohlsson, has decided to conclude her assignment as a consultant. "During her time as CFO, Anja has contributed with a high level of competence, structure, and professionalism to the company's financial operations. The Board of Directors and management would like to express their sincere...

HOLZMINDEN (dpa-AFX) - Symrise AG announced that it is in advanced discussions with potential buyers regarding the divestment of its terpenes business. The process is being conducted as a structur......

Synsam AB (publ) (LEI code: 5493000TMEGW9DHNOQ70) ("Synsam" or the "Company") has during January 5, 2026, to January 9, 2026, repurchased in total 70,000 own shares (ISIN code: SE0016829709) as part of the share buy-back program initiated by the board of directors of Synsam in order to adjust the Company's capital structure. The repurchases form part of the share buy-back program of maximum MSEK 160 announced by Synsam on August 21, 2025, and which runs during the period from August 25, 2025, until February 27, 2026. The share buy-back program is being carried out in accordance with the EU...

Lund, Sweden – January 12, 2026 – Phase Holographic Imaging PHI AB (PHI), a pioneer in advanced holographic imaging solutions for life sciences, today announces its intention to file for bankruptcy with the Swedish District Court on January 12, 2026. Despite significant efforts to secure long-term financing and strategic partnerships, PHI has faced persistent financial challenges due to slower-than-expected market adoption and limited access to capital. After careful consideration of all available options, the Board of Directors has determined that filing for bankruptcy is the most...

Diamyd Medical today announced that the screening period in its pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals with type 1 diabetes has been completed. Based on the number of patients screened, the Company expects approximately 310–320 participants to be randomized into the trial once enrollment is completed, which is expected by early March. “The completion of screening is a key milestone for DIAGNODE-3 and confirms strong operational momentum in our pivotal genetically defined Phase 3 program,” says Ulf Hannelius, CEO of Diamyd Medical. “With enrollment...

STOCKHOLM – 12 January 2026 – Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 19 December 2025 regarding the final results of the fully guaranteed private placement (the "Private Placement"). Further, reference is made to the stock exchange announcement made by the Company on 17 December 2025 and previous announcements regarding the fully guaranteed repair issue of 2,304,563 new shares (the "Repair Issue"). The Repair Issue will be directed pro-rata towards existing shareholders that did not participate in the Private Placement and who...

The renovated produce arcade is the first new Market experience to open as a part of the Market's $70 million transformation project CLEVELAND, OH / ACCESS Newswire / January 9, 2026 / West Side Ma......

STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue of shares of approximately SEK 83 million (the "Rights Issue") resolved by the Board of Directors of......

PDUFA target action date set to 10 June 2026 LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029),......

Diamyd Medical today announced that its investigational antigen-specific immunotherapy for type 1 diabetes, commonly referred to as Diamyd, has been assigned the global non-proprietary name “retogatein” by the World Health Organization's International Nonproprietary Names (INN) Programme and the United States Adopted Names Council (USAN). “The assignment of the non-proprietary name retogatein represents an important milestone in the development of our precision immunotherapy for type 1 diabetes,” says Ulf Hannelius, CEO of Diamyd Medical. “The INN and USAN provide a standardized global...

Gothenburg, January 9, 2025 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announces final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases. The study demonstrates that ELC-100, was generally well-tolerated with no dose-limiting toxicities observed. Importantly, the...

STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the "Company") today announces the outcome of the repurchase offer for all warrants of series TO 2 resolved by the Board of Directors on 7 November 2025 (the "TO 2 Offer"). The outcome shows that holders of a......

Today, the 9[th] of January 2026, an extraordinary general meeting was held in SyntheticMR AB (publ). Below is a summary of the decisions made, the complete proposal for the decisions can be found on the company's website: https://syntheticmr.com/investors/corporate-governance/. All decisions were made unanimously. Item 6: Resolution regarding approval of the board's resolution on a rights issue of shares The general meeting decided to approve the board's resolution on a rights issue of a maximum of 29,777,342 shares as follows: The subscription price to be paid for each share...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KAROLINSKA DEVELOPMENT AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW....

The Board of Directors of PixelFox AB (the “Company” or “PixelFox”) has resolved to convene an Extraordinary General Meeting to decide on a distribution of shares in Servana AB. The Board's proposal entails that PixelFox distributes approximately 2,000,000,000 shares (approx. 28%) in Servana AB to PixelFox's shareholders. Following completion of the distribution, PixelFox's ownership interest in Servana AB is expected to amount to approximately 47 percent. Purpose and rationale The purpose of the distribution is to broaden the ownership base in Servana AB and thereby create conditions...